Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

American journal of hematology·2026
Same author

Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.

Nature reviews. Rheumatology·2026
Same author

Giant Cell Arteritis.

Annals of internal medicine·2026
Same author

Significance of positive rheumatoid factor in ANCA-associated vasculitis.

Clinical and experimental rheumatology·2026
Same author

Structured Vascular Segment Analysis for Giant Cell Arteritis: A Proposed Scoring System for CT Angiography-Based Diagnosis.

AJNR. American journal of neuroradiology·2026
Same author

A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis.

Seminars in arthritis and rheumatism·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
查看所有相关文章

相关实验视频

多重肌痛类风湿症 多重肌痛类风湿症

Tanaz A Kermani1, Kenneth J Warrington

  • 1Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Lancet (London, England)
|October 12, 2012
PubMed
概括
此摘要是机器生成的。

多发性肌痛类风湿症是一种炎症性疾病,在老年人中引起疼痛和硬. 诊断依赖于临床评估,虽然糖皮质激素有帮助,但复发和副作用很常见,需要更好的治疗方法.

相关实验视频

科学领域:

  • 类风湿病学 类风湿病学
  • 免疫学 免疫学 免疫学
  • 内部医学 内部医学

背景情况:

  • 多发性肌痛性风湿症 (PMR) 是一种慢性炎症性疾病,影响50岁以上的人.
  • 它的特点是部,肩膀,部和大腿的疼痛和早晨硬.
  • 诊断是临床的,因为没有特定的实验室测试存在,尽管炎症标志物可能会升高.

研究的目的:

  • 要总结多肌痛性风湿症的关键方面.
  • 突出诊断挑战和当前的治疗方法.
  • 强调需要更好地了解疾病的发病因子.

主要方法:

  • 临床评估和临时分类标准 (2012年EULAR/ACR).
  • 对显示关节周炎症的成像研究 (超声波,MRI) 的审查.
  • 在一组患者中与大动脉血管病变 (巨细胞动脉炎) 相关.

主要成果:

  • PMR症状往往模仿其他炎症性关节病,如脊髓关节炎和类风湿性关节炎.
  • 图像显示主要是关节周炎症过程.
  • 葡萄糖皮质激素治疗提供了症状缓解,但与频繁复发和显著的发病率有关.

结论:

  • 多发性肌痛类风湿症的诊断仍然是临床基础的,与其他炎症状况区分它存在挑战.
  • 目前使用葡萄糖皮质激素的标准治疗对于症状管理是有效的,但有局限性.
  • 对PMR病原学的进一步研究对于开发更有针对性的免疫疗法至关重要.